- Home
- GLBS vs BCAB Comparison
GLBS vs BCAB Comparison
Compare GLBS & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLBS
- BCAB
- Stock Information
- Founded
- GLBS 2006
- BCAB 2007
- Country
- GLBS Greece
- BCAB United States
- Employees
- GLBS N/A
- BCAB N/A
- Industry
- GLBS Marine Transportation
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- GLBS Consumer Discretionary
- BCAB Health Care
- Exchange
- GLBS Nasdaq
- BCAB Nasdaq
- Market Cap
- GLBS 23.4M
- BCAB 21.0M
- IPO Year
- GLBS 2007
- BCAB 2020
- Fundamental
- Price
- GLBS $1.04
- BCAB $0.33
- Analyst Decision
- GLBS Strong Buy
- BCAB Buy
- Analyst Count
- GLBS 1
- BCAB 2
- Target Price
- GLBS $3.00
- BCAB $1.00
- AVG Volume (30 Days)
- GLBS 27.3K
- BCAB 816.4K
- Earning Date
- GLBS 09-11-2025
- BCAB 08-11-2025
- Dividend Yield
- GLBS N/A
- BCAB N/A
- EPS Growth
- GLBS N/A
- BCAB N/A
- EPS
- GLBS N/A
- BCAB N/A
- Revenue
- GLBS $35,776,000.00
- BCAB $11,000,000.00
- Revenue This Year
- GLBS $5.01
- BCAB N/A
- Revenue Next Year
- GLBS $27.86
- BCAB N/A
- P/E Ratio
- GLBS N/A
- BCAB N/A
- Revenue Growth
- GLBS 17.92
- BCAB N/A
- 52 Week Low
- GLBS $0.99
- BCAB $0.24
- 52 Week High
- GLBS $2.21
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- GLBS 37.36
- BCAB 38.71
- Support Level
- GLBS $1.00
- BCAB $0.33
- Resistance Level
- GLBS $1.23
- BCAB $0.37
- Average True Range (ATR)
- GLBS 0.06
- BCAB 0.04
- MACD
- GLBS -0.01
- BCAB -0.00
- Stochastic Oscillator
- GLBS 16.00
- BCAB 5.26
About GLBS Globus Maritime Limited
Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.